<DOC>
	<DOC>NCT01059825</DOC>
	<brief_summary>MK-8835-016 (B1521006) is designed to evaluate the safety and efficacy of an investigational drug, ertugliflozin (MK-8835, PF-04971729) in participants with Type 2 diabetes mellitus. Participants in the study will receive 1 of 6 treatments for 12 weeks including 1 treatment with an approved drug (sitagliptin) for the treatment of Type 2 diabetes mellitus.</brief_summary>
	<brief_title>Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Patients with type 2 diabetes on stable doses of background medicines for management of the diabetes; aged 1870 years; body mass index between 2345 kg/m2 Patients with type 1 diabetes, heart attack or stroke in last 6months, uncontrolled blood pressure, significant kidney disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Phase 2</keyword>
	<keyword>safety and efficacy study with ertugliflozin (PF-04971729, MK-8835)</keyword>
	<keyword>Type 2 diabetes mellitus</keyword>
</DOC>